Sanai Health Industry Group Co (HKSE:01889) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01889 Sanai Health Industry Group Co Ltd HKSE:01889
40 GF Score
Price HK$0.19
GF Value HK$0.42
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sanai Health Industry Group Co FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:01889
40GF Score
Sanai Health Industry Group Co Ltd HKSE:01889
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sanai Health Industry Group Co (HKSE:01889) Overvalued in 2026?

Based on GuruFocus' analysis, Sanai Health Industry Group Co stock appears to be undervalued. The current stock price of HK$0.19 is trading 53.8% below its estimated GF Value™ of HK$0.42. GuruFocus considers Sanai Health Industry Group Co to be Possible Value Trap.

Key valuation signals for HKSE:01889:

  • FFO:
  • GF Value™: HK$0.42 vs. price of HK$0.19 (53.8% below fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the HKSE:01889 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sanai Health Industry Group Co Business Description

Address 57 Hung To Road, Unit 5, 7th Floor, Nanyang Plaza, Kwun Tong, Kowloon, Hong Kong, HKG
Sanai Health Industry Group Co Ltd is a pharmaceutical company. The company has three reportable segments namely Pharmaceutical products include development, manufacturing, marketing, and sales of pharmaceutical products and related software and provision of consultancy services. Finance leasing includes the provision of financial leasing services; Genetic testing and molecular diagnostic services segment. It generates maximum revenue from Pharmaceutical products segments. Geographically, it derives the majority of its revenue from the PRC.
40GF Score

Get the complete analysis for HKSE:01889

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.19
Price
HK$0.42
GF Value